Risankizumab: Efficacy, Safety, and Survival in the Mid-Term (52 Weeks) in Real Clinical Practice in Andalusia, Spain, According to the Therapeutic Goals of the Spanish Psoriatic Guidelines

Risankizumab: Efficacy, Safety, and Survival in the Mid-Term (52 Weeks) in Real Clinical Practice in Andalusia, Spain, According to the Therapeutic Goals of the Spanish Psoriatic Guidelines

Introduction. Risankizumab is a humanized monoclonal antibody of the immunoglobulin G1 (IgG1) type that binds selectively, and with high affinity, to the p19 subunit of interleukin-23 (IL-23), resulting in the inhibition of inflammation and clinical symptoms associated with psoriasis. Its introducti...

Full description

Bibliographic Details
Main Authors: Ricardo Ruiz-Villaverde, Lourdes Rodriguez-Fernandez-Freire, Amalia Pérez-Gil, Pilar Font-Ugalde, Manuel Galán-Gutiérrez
Format: Article
Language:English
Published: MDPI AG 2022-11-01
Series:Life
Subjects:
risankizumab
psoriasis
long-term
real-world evidence
Online Access:https://www.mdpi.com/2075-1729/12/11/1883

Similar Items

Similar Items